These data confirm the debilitating effects of apathy on functioning in patients with Huntington disease.
The authors noted that apathy is very common and progressive among Huntington disease mutation carriers, even during early stages of the disease, and has been associated with decline in general functioning.
Electrical stimulation of the amygdala may boost declarative memory without influencing an emotional response.
The HD-associated CAG repeat with 36 or more repeats was found in 18 individuals.
The FDA has accepted Teva's New Drug Application for deutetrabenazine to treat chorea associated with Huntington's disease.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Predictors of Long-term Medication Adherence in Children With ADHD
- Influence of Psychostimulants on BMI and Height in Youth With ADHD
- Medication Adherence Predictors in Patients With Severe Psychiatric Disorders
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Substance Abuse and Primary Psychosis: A Closer Look
- Functional Restoration for Chronic Pain and Depression in the Elderly: Pharmacotherapy and Beyond
- Efficacy of Long-Acting Injectable Antipsychotics vs Oral Antipsychotics
- Older Age Associated With Worse Major Depressive Disorder Outcomes
- Preoperative Psychiatric Diagnoses Not Associated With Bariatric Surgery Outcomes
- Medical Clearance of Psych Patients in the ED: Consensus Recommendations